{"classes":[{"categories":[{"measurements":[{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"8.0","upperLimit":"NA","value":"17.4"},{"groupId":"OG001","lowerLimit":"12.9","upperLimit":"33.7","value":"23.5"},{"groupId":"OG002","lowerLimit":"6.3","upperLimit":"23.4","value":"13.3"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG003","lowerLimit":"12.9","upperLimit":"NA","value":"41.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"25"},{"groupId":"OG003","value":"24"}],"units":"Participants"}],"description":"OS is defined as the interval of time between the first dose of study medication until the date of death due to any cause. For the participants who did not die, overall survival was censored at the date of last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 75 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available pharmacokinetic (PK), safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on dose-limiting toxicities (DLTs) occurring during the first 3 weeks of treatment.","id":"OG000","title":"Part B: Dabrafenib 75 mg + Trametinib 1 mg"},{"description":"Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors and participants who had salivary ductal cancer received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.","id":"OG001","title":"Part B: Dabrafenib 150 mg + Trametinib 1 mg"},{"description":"Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 150 mg gelatin capsules BID and trametinib 1.5 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.","id":"OG002","title":"Part B: Dabrafenib 150 mg + Trametinib 1.5 mg"},{"description":"Melanoma BRAF-positive participants who received prior treatment with BRAF inhibitors and participants who had colorectal cancer and BRAFi naïve melanoma received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD as continuous daily dosing. Dose escalation did not proceed beyond these doses of dabrafenib and trametinib.","id":"OG003","title":"Part B: Dabrafenib 150 mg + Trametinib 2 mg"}],"paramType":"MEDIAN","populationDescription":"All Treated Population.","reportingStatus":"POSTED","timeFrame":"From the date of first dose until date of death due to any cause (up to approximately 8 years)","title":"Part B: Overall Survival (OS) in BRAFi Naïve Melanoma Participants","type":"SECONDARY","unitOfMeasure":"Months"}